Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck

  • Authors:
    • Andreas E. Albers
    • Regina Grabow
    • Xu Qian
    • Masen D. Jumah
    • Veit M. Hofmann
    • Alexander Krannich
    • Gabriele Pecher
  • View Affiliations

  • Published online on: June 1, 2017     https://doi.org/10.3892/mco.2017.1281
  • Pages: 151-157
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate the clinical effectiveness and toxicity of docetaxel with 5-fluorouracil and cisplatin as combination treatment in patients with curable or metastatic/recurrent head and neck cancer by a retrospective cohort study of patients treated at a single institution between 2007 and 2012. Patients with locally advanced, metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN), who were treated with a combination therapy including docetaxel, were considered as eligible. Survival data, clinical side effects, quality of life (QoL) and toxicity profile were retrieved from patient charts, analyzed and scored according to the National Cancer Institute Common Toxicity Criteria, version 4, and the Response Evaluation Criteria In Solid Tumors, version 1.1. An overall response rate of 86% and a 3‑year survival of 65.1% were observed. The median progression‑free survival was 32 months. The cumulative incidence after 3 years was 16.9% for local recurrence and 10.4% for distant metastasis. Leukopenia (58%) and anemia (51%) were the most common hematological toxicities, followed by hepatotoxicity (53%) and nausea (27%). A total of 31% of the patients experienced a compromise in their QoL following therapy completion. In conclusion, docetaxel in combination with cisplatin and 5‑fluorouracil was found to effectively prolong survival in patients with locally advanced and/or recurrent metastatic SCCHN. The overall survival, progression‑free survival and response rates were in accordance with those reported by previous clinical trials. Therefore, this therapy protocol is recommended for patients with SCCHN in the curative as well as the palliative settings.
View Figures
View References

Related Articles

Journal Cover

July 2017
Volume 7 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Albers, A.E., Grabow, R., Qian, X., Jumah, M.D., Hofmann, V.M., Krannich, A., & Pecher, G. (2017). Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck. Molecular and Clinical Oncology, 7, 151-157. https://doi.org/10.3892/mco.2017.1281
MLA
Albers, A. E., Grabow, R., Qian, X., Jumah, M. D., Hofmann, V. M., Krannich, A., Pecher, G."Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck". Molecular and Clinical Oncology 7.1 (2017): 151-157.
Chicago
Albers, A. E., Grabow, R., Qian, X., Jumah, M. D., Hofmann, V. M., Krannich, A., Pecher, G."Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck". Molecular and Clinical Oncology 7, no. 1 (2017): 151-157. https://doi.org/10.3892/mco.2017.1281